@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAutoTcLZyZZ9BkAIV93cS3dONO886sffpiH_oghN66wk> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAutoTcLZyZZ9BkAIV93cS3dONO886sffpiH_oghN66wk#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix RNA: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_33697> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: hgnc:1590;
    a RNA: .
  
  sub:_2 occursIn: do:219, species:9606;
    rdf:object sub:_1;
    rdf:predicate belv:decreases;
    rdf:subject chebi:40877;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(CHEBI:erlotinib) -| r(HGNC:CCNE2)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "20131211" .
  
  sub:_3 prov:value "About 35 mRNAs were dysregulated in the erlotinib-treated group, whereas no significant change in the mRNAs from the celecoxib alone?treated group was found. Analysis of these results revealed that a large subset of genes involved in cell cycle progression or cellular proliferation was differentially regulated. The effect of celecoxib and erlotinib on mRNA levels of these genes are summarized in Table 1 . (HCA-7 cells, a human colorectal cancer cell line, were injected s.c. into the flank region of athymic nu/nu mice.) ";
    prov:wasQuotedFrom pubmed:17909047 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:17909047;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:33:12.945+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}